Bvf Inc 4 D Molecular Therapeutics, Inc. Transaction History

Bvf Inc

$2.54 Billion
Q2 2025

A detailed history of Bvf Inc transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Bvf Inc holds 4,629,289 shares of FDMT stock, worth $28.5 Million. This represents 0.67% of its overall portfolio holdings.

Number of Shares

4,629,289

Previous 4,561,289 1.49%

Holding current value

$28.5 Million

Previous $14.7 Million 16.58%

% of portfolio

0.67%

Previous 0.65%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.51 - $4.79 $170,680 - $325,720	68,000 Added 1.49%	4,629,289 $17.2 Million
Q1 2025 May 15, 2025	BUY	$3.23 - $6.6 $6.11 Million - $12.5 Million	1,890,647 Added 70.79%	4,561,289 $14.7 Million
Q4 2024 Feb 14, 2025	SELL	$5.3 - $10.41 $25 Million - $49.1 Million	-4,712,000 Reduced 63.83%	2,670,642 $14.9 Million
Q3 2024 Nov 14, 2024	BUY	$10.81 - $27.22 $37.4 Million - $94.2 Million	3,460,229 Added 88.22%	7,382,642 $79.8 Million
Q1 2024 May 15, 2024	SELL	$17.03 - $35.87 $1.45 Million - $3.05 Million	-85,000 Reduced 2.12%	3,922,413 $125 Million
Q2 2022 Aug 15, 2022	BUY	$5.68 - $15.99 $7.63 Million - $21.5 Million	1,342,892 Added 50.4%	4,007,413 $28 Million
Q1 2022 May 16, 2022	BUY	$13.16 - $22.64 $8.67 Million - $14.9 Million	658,659 Added 32.84%	2,664,521 $40.3 Million
Q2 2021 Aug 16, 2021	BUY	$22.2 - $42.29 $21.6 Million - $41.2 Million	974,792 Added 94.54%	2,005,862 $48.3 Million
Q1 2021 May 17, 2021	SELL	$35.94 - $52.67 $2.7 Million - $3.95 Million	-75,000 Reduced 6.78%	1,031,070 $44.7 Million
Q4 2020 Feb 12, 2021	BUY	$38.43 - $47.36 $42.5 Million - $52.4 Million	1,106,070 New	1,106,070 $45.8 Million

Others Institutions Holding FDMT

# of Institutions

124

Shares Held

41.2M

Call Options Held

19K

Put Options Held

38.3K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $199M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.

Account